Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with prev...
Main Authors: | Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frédéric Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann-Lii Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2022-10-01
|
Series: | Liver Cancer |
Online Access: | https://www.karger.com/Article/FullText/527175 |
Similar Items
-
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
by: Liman Huo, et al.
Published: (2023-10-01) -
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
by: Anthony B. El-Khoueiry, et al.
Published: (2022-04-01) -
Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
by: Nageshwar Budha, et al.
Published: (2023-01-01) -
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors
by: Tian Yu, et al.
Published: (2024-03-01) -
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
by: Zhongchao Li, et al.
Published: (2024-04-01)